Status:
COMPLETED
Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
Lead Sponsor:
Ipsen
Conditions:
Renal Cell Carcinoma
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this Post Marketing Surveillance (PMS) is to collect and describe safety and effectiveness profile of Cabometyx™ in real clinical practice setting, according to the approved labelling...
Eligibility Criteria
Inclusion
- Patients who meet 'Indications' of label for Cabometyx™ as monotherapy
- Patients who are treated with Cabometyx™ for the first time according to label for Cabometyx™ as monotherapy
- Patients who are aged 18 years or older
- Patients who are willing to provide written consent after being informed of this surveillance
Exclusion
- Patients who are contraindicated for Cabometyx™ based on Cabometyx™ label
Key Trial Info
Start Date :
May 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 26 2024
Estimated Enrollment :
347 Patients enrolled
Trial Details
Trial ID
NCT03776123
Start Date
May 15 2019
End Date
March 26 2024
Last Update
May 29 2024
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
Korea University Ansan Hospital
Ansan, South Korea, 15355
2
Hallym University Sacred Heart Hospital
Anyang, South Korea, 14068
3
DONG-A University Hospital (Site A)
Busan, South Korea, 49201
4
DONG-A University Hospital (Site B)
Busan, South Korea, 49201